Kobayashi M et al. |
FK 506 assay past and present--characteristics of FK 506 ELISA. |
1991 |
Transplant. Proc. |
pmid:1721258
|
Warty VS et al. |
Practical aspects of FK 506 analysis (Pittsburgh experience). |
1991 |
Transplant. Proc. |
pmid:1721259
|
Jusko WJ and D'Ambrosio R |
Monitoring FK 506 concentrations in plasma and whole blood. |
1991 |
Transplant. Proc. |
pmid:1721260
|
Venkataramanan R et al. |
Pharmacokinetics of FK 506 in transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721261
|
Loréal O et al. |
FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. |
1991 |
Transplant. Proc. |
pmid:1721289
|
McCauley J et al. |
Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. |
1991 |
Transplant. Proc. |
pmid:1721290
|
McLachlan G et al. |
Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. |
1991 |
Transplant. Proc. |
pmid:1721291
|
Akselband Y et al. |
Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. |
1991 |
Transplant. Proc. |
pmid:1721292
|
Fukuzawa M et al. |
Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. |
1991 |
Transplant. Proc. |
pmid:1721321
|
Takaori K et al. |
Effects of FK 506 on in vivo immunity in comparison to cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721322
|
Jordan ML et al. |
Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. |
1991 |
Transplant. Proc. |
pmid:1721323
|
Motta I et al. |
FK 506 favors the generation of memory T cells in vitro. |
1991 |
Transplant. Proc. |
pmid:1721324
|
Paul AA et al. |
CMV retinitis and the use of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721354
|
Keicho N et al. |
Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. |
1991 |
Cell. Immunol. |
pmid:1703047
|
Reyes J et al. |
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721355
|
White DJ |
FK506: the promise and the paradox. |
1991 |
Clin. Exp. Immunol. |
pmid:1703053
|
Whiteside TL et al. |
Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. |
1991 |
Transplant. Proc. |
pmid:1721356
|
Frayha HH et al. |
Lymphoproliferative disorder in a liver transplant patient on FK 506. |
1991 |
Lancet |
pmid:1703258
|
Van Thiel DH et al. |
Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721357
|
Burman K and Crawford DH |
Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. |
1991 |
Lancet |
pmid:1703259
|
Tauxe WN et al. |
A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721386
|
McCauley J et al. |
Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721387
|
Hossein-Nia M et al. |
Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. |
1991 |
Transplant. Proc. |
pmid:1721388
|
Winkler M et al. |
Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. |
1991 |
Transplant. Proc. |
pmid:1721389
|
Masaoka T et al. |
Phase II study of FK 506 for allogeneic bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721417
|
Markus PM et al. |
The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721418
|
Cooper MH et al. |
The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. |
1991 |
Transplant. Proc. |
pmid:1721419
|
Boggs S et al. |
FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. |
1991 |
Transplant. Proc. |
pmid:1721420
|
Goebl MG |
The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. |
1991 |
Cell |
pmid:1706222
|
de Paulis A et al. |
FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. |
1991 |
J. Immunol. |
pmid:1706398
|
Griffiths EJ and Halestrap AP |
Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. |
1991 |
Biochem. J. |
pmid:1706598
|
Abu-Elmagd K et al. |
FK 506: a new therapeutic agent for severe recalcitrant psoriasis. |
1991 |
Transplant. Proc. |
pmid:1721449
|
Nikolaidis NL et al. |
Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. |
1991 |
Transplant. Proc. |
pmid:1721450
|
Abu-Elmagd K et al. |
Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. |
1991 |
Transplant. Proc. |
pmid:1721451
|
Aoki H |
[FK 506, a new immunosuppressant produced by a Streptomyces]. |
1991 |
Nippon Rinsho |
pmid:1712403
|
Hultsch T et al. |
Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1712484
|
Miyahara H et al. |
Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. |
1991 |
Clin. Immunol. Immunopathol. |
pmid:1712688
|
McAlpine JB et al. |
Revised NMR assignments for rapamycin. |
1991 |
J. Antibiot. |
pmid:1712766
|
Katz IA et al. |
Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. |
1991 |
Transplantation |
pmid:1716801
|
Jiang H et al. |
Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. |
1991 |
Eur Surg Res |
pmid:1723683
|
Pezze JL and Whiteman K |
Transplantation's newest weapon FK 506. |
1991 |
Am J Nurs |
pmid:1716857
|
Fung JJ et al. |
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. |
1991 |
Transplant. Proc. |
pmid:1703682
|
Marquis-Omer D et al. |
Stabilization of the FK506 binding protein by ligand binding. |
1991 |
Biochem. Biophys. Res. Commun. |
pmid:1716886
|
Wu J et al. |
Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. |
1991 |
Transplant. Proc. |
pmid:1703683
|
Sakai K et al. |
[The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. |
1991 |
No To Shinkei |
pmid:1716937
|
Flanagan WM et al. |
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. |
1991 |
Nature |
pmid:1715516
|
McWhinnie DL and Morris PJ |
Combination drug therapies for immunosuppression in transplantation. |
1991 |
Ann. Acad. Med. Singap. |
pmid:1724724
|
Pourtier-Manzanedo A et al. |
FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. |
1991 |
Anticancer Drugs |
pmid:1724925
|
Nakahama H et al. |
Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. |
1991 |
J. Cardiovasc. Pharmacol. |
pmid:1725322
|
Romanowski P et al. |
[Synthetic immunomodulators designed on the basis of natural products of microorganisms]. |
1991 |
Postepy Biochem. |
pmid:1725924
|